hepatocellular carcinoma
43 all articles · 20 / page
Latest news
Tag
Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen
This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.
Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients
Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.
Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study
Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental
Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional
Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp
HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint
RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice
A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.
Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.
Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results
A prospective trial found that non-contrast abbreviated MRI detected hepatocellular carcinoma in cirrhotic patients far better than ultrasound, with most MRI-detected tumors found at an early, potentially curable stage.
A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma
A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i
Uncoupling Metabolic Reprogramming in Hepatocellular Carcinoma: The JOSD1-PGAM1 Ubiquitination-Lactylation Switch
This article explores how the deubiquitinase JOSD1 drives HCC progression by modulating a novel PTM switch on PGAM1, promoting glycolysis and immune evasion while providing a new target for combined immunotherapy.
A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models
The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.
Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris
Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma
Researchers have developed an AI-powered framework that uncovers a non-linear relationship between tumor-stroma ratio and mortality in hepatocellular carcinoma, using a novel token-guided multimodal fusion approach to improve prognostic acc
The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer
A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease
Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy
A groundbreaking multicentre study develops a clinical-radiologic model integrating hypoxia and immune phenotype signatures to accurately predict prognosis in hepatocellular carcinoma patients treated with transarterial chemoembolisation, p
Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis
This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy
Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an
Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial
This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi
TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer
This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.